Oura announced on Monday that it is launching a newly redesigned app experience and a new feature called Cumulative Stress. The company also shared that it is pursuing FDA clearance for future blood pressure features that would give users a likelihood assessment of hypertension.
The redesigned Oura app introduces more personalization with three main tabs. The Today tab surfaces the most relevant insights for daily decisions. The Vitals tab provides at-a-glance views of metrics like sleep, stress, and cardiovascular trends. The My Health tab offers insights into the user’s long-term well-being, highlighting strengths, trends, and opportunities for proactive care. This tab also includes Habits and Routines sections to show the impact of daily actions.
The app redesign also brings enhanced menstrual cycle insights. This update includes a twelve-month view of period and fertile window predictions, a significant increase from the previous one-month view.
The new Cumulative Stress feature helps users understand how their bodies accumulate and respond to chronic stress over time. It provides a stress measurement based on the past month of data and is updated weekly. A person’s Cumulative Stress is determined by five factors: sleep continuity, heart stress-response, sleep micro-motions, temperature regulation, and activity impact.
An Oura executive explained that the feature is more than just tallying stressful hours. It actually measures different bodily functions that indicate cumulative stress is taking a toll. This includes how heart rate and heart rate variability respond after a period of stress, how you regulate temperature overnight, how continuous your sleep is, and whether you experience small twitches called sleep micro-motions. These little signatures are indicative of the body experiencing high cumulative stress. The new feature will roll out globally in the coming weeks.
On the road to developing an FDA-approved blood pressure feature, Oura announced it is introducing a new Blood Pressure Profile study. This study will explore how the company can identify early signs of hypertension by passively tracking key signals in the background.
Oura received approval from the Institutional Review Board for this study, which is launching in the experimental hub Oura Labs in the U.S. later this year. Users who are part of the study will be notified of their current likelihood of hypertension. This assessment combines Oura Ring data with a short check-in questionnaire on family history, medication, and lifestyle habits. They will receive an assessment that lets them know if they have no signs, moderate signs, or major signs of hypertension. Members with strong signs will be encouraged to seek professional medical care. The algorithm will also track changes over time, prompting periodic reviews throughout the study.
Monday’s announcement comes a week after Oura raised nine hundred million dollars in fresh funding led by Fidelity Management and Research Company, with participation from new investor ICONIQ and contributions from Whale Rock and Atreides.
It also comes as Oura recently launched its Oura Ring 4 Ceramic collection, its first-ever charging case, and a new Health Panels feature that lets members schedule blood work directly in the Oura app.